In women with postmenopausal osteoporosis undergoing fusion surgery, preoperative teriparatide was linked to higher screw insertional torque than no teriparatide.
In plain wordsIn women with osteoporosis undergoing fusion surgery, preoperative teriparatide was linked to higher screw insertional torque than no teriparatide.
- Peptide
- Teriparatide (PTH 1-34)
- Outcome
- IncreasePedicle screw insertional torque
- Study
n = 29
- Comparator
- No preoperative teriparatide
- Outcome group
- Bone and joint · Musculoskeletal
- Studied dose
- 20 μg/day (daily, n = 7) or 56.5 μg/week (weekly, n = 6) · injection · Mean 61.4 days; minimum 31 daysAs given in this study (human).
Measurements
- Insertional torque
- 1.28 Nm
- teriparatide
- Insertional torque
- 1.08 Nm
- control
Source sentences
The mean insertional torque value in the teriparatide group was 1.28 ± 0.42 Nm, which was significantly higher than in the control group (1.08 ± 0.52 Nm, p < 0.01).
3 context sentences(design, population, supporting numbers)
Fusion surgery for the thoracic and/or lumbar spine was performed in 29 postmenopausal women with osteoporosis aged 65-82 years (mean 72.2 years).
The patients were divided into 2 groups based on whether they were treated with teriparatide (n = 13) or not (n = 16) before the surgery.
In the teriparatide-treated group, patients received preoperative teriparatide therapy as either a daily (20 μg/day, n = 7) or a weekly (56.5 μg/week, n = 6) injection for a mean of 61.4 days and a minimum of 31 days.